← All companies
MIT
Caltech
AbInitio Bio
ActiveThe Intelligence layer for Drug Manufacturing
Spring 2026Founded 20261 peopleSan Francisco, CA, USA
AI insightcan contain mistakes
Pharma Manufacturing AISaaSPharmaceutical manufacturers, biotech production facilitiesLow competition
Moat
Domain expertise in drug manufacturing; regulatory compliance integration; process optimization algorithms.
Key risk
Regulatory approval barriers (FDA, EMA); manufacturing complexity and data scarcity; limited to pharma vertical.
Why now
Pharma production cost inflation; supply chain disruptions; AI-driven process optimization proving ROI.
Competitors
Emerging space, traditional MES systems
Founders · 1
Daniel MukasaFounder & CEO
Founder & CEO at AbInitio Bio (YC P26). Postdoctoral Fellow at MIT focused on AI and drug discovery. Previously AI/ML intern at Merck working on antibody therapeutic design. PhD in Applied Physics and Materials Science from Caltech.
Launch
Launched on Y Combinator · May 2026
View launch post ↗Foundation models for Biomanufacturing
Abinitio Bio announces Echo, the first foundation models for biomanufacturing that use validated wet-lab data to predict manufacturing outcomes. The model aims to transfer across products to reduce decision timelines from 6-18 months to hours, targeting pharma, biotech, and CDMOs involved in biologics, multispecifics, and CMC risk.
Related startups
Synthio LabsSpring 2025
Agentic AI platform for Pharma GTM teams
Active
InferaSpring 2026
Control lab instruments with natural language.
Laboratory Automation AIActive
